Editorial commentary on 'Analysis of IDH mutation, 1p19q deletion, and PTEN loss delineates prognosis in clinical low-grade gliomas'

摘要

In this issue of Neuro-Oncology, Sidney Croul and his colleagues report that IDH mutation, 1p/19q codeletion, and PTEN loss can be used to predict prognosis in patients with low-grade (grade 2-3) gliomas. In recent years, neuro-oncologists have learned that a significant portion of low-grade gliomas acquire mutations in the IDH1 and IDH2 genes and that these mutations are associated with a better prognosis. Similarly, 1p/19q codeletion has both prognostic and predictive value in low-grade gliomas with oligodendroglial components. Recently, Cairncross et al. have shown, using patients enrolled in the RTOG trial 9402, that together IDH mutation and 1p/19q codeletion status are strong predictors of prognosis and response to therapy in grade 3 gliomas with an oligodendroglial component.